Global Budget Revenue Model and Care for Patients Receiving Chemotherapy
JAMA Network Open · 05.03.2026 · 9 (3) · e260485
DOI: 10.1001/jamanetworkopen.2026.0485 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 05.03.2026. Verfasst von Yu-Li Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Medicare, Neoplasms, Budgets, Antineoplastic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance Maryland’s Global Budget Revenue (GBR) model provided fixed global payments to hospitals, aiming to control revenue growth while improving care quality. The implications of GBR implementation in 2014 for cancer care have not been robustly evaluated.
Objective
To examine the association between GBR implementation and subsequent changes in episode-based Medicare payments, hospital utilization, and quality of care among Medicare beneficiaries undergoing systemic therapy for cancer. Design, Setting, and Participants This cohort study used a difference-in-differences approach to compare changes in outcome measures from pre-GBR (2011-2013) to post-GBR (2014-2018) implementation periods in Maryland compared with 11 control states. Six-month care episodes were selected for adult fee-for-service Medicare beneficiaries initiating or continuing cytotoxic chemotherapy, immunotherapy, or targeted therapy for cancer between 2011 and 2018. Data were obtained from Medicare claims, including inpatient, outpatient, carrier, durable medical equipment, home health agency, hospice, and Part D event files. All analyses were performed between April 4, 2024, and January 5, 2026. Main Outcomes and Measures The primary outcomes were standardized Medicare payments during the 6-month systemic therapy episode, including total, hospital, and professional payments. Also assessed were measures of hospital-based utilization (all-cause hospitalizations and emergency department [ED] visits) and care quality (timely receipt of chemotherapy; chemotherapy-related hospitalizations and ED visits; and measures of high-intensity end-of-life treatment: no or late hospice enrollment, >1 ED visit in the last 30 days of life, intensive care unit stay in the last 30 days of life, and receipt of chemotherapy in the last 14 days of life).
Results
A total of 38 531 chemotherapy episodes in Maryland were matched to 38 531 episodes in control states. Episodes in Maryland were for patients (22 185 females [57.6%]) with a mean (SD) age of 73.3 (8.6) years; in control states, episodes were for patients (21 708 females [56.3%]) with a mean (SD) age of 72.7 (9.1) years. GBR implementation was associated with a reduction of $3075 (95% CI, −$4276 to −$1843; 6.1% savings) in total episode payments, a reduction of $3217 (95% CI, −$4058 to −$2328; 17.3% savings) in hospital payments, and an increase of $1382 (95% CI, $781-$2013; 11.9% increase) in professional payments. There was a reduction of 1.7 (95% CI, −3.0 to −0.5) percentage points in chemotherapy-related hospitalizations. No significant association was found for other hospital-based utilization or care quality measures. Conclusions and Relevance This cohort study of patients with systemic anticancer therapy episodes showed that Maryland’s GBR model was associated with substantial reductions in the growth of Medicare payments. These savings may have been achieved by shifting care toward lower-cost treatment settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston.
- Department of Economics, University of New Hampshire Paul College of Business and Economics, Durham.
- Department of Health Management and Policy, University of New Hampshire College of Health and Human Services, Durham.
- Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston.
- Division of Palliative Care and Geriatrics, Massachusetts General Hospital, Boston.
- Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts.
Förderung
- NCI NIH HHS
Zitieren
APA
Lin, Y. L., Herring, B., Melamed, A., Petrillo, L. A., Keating, N. L., & Offodile, A. C. (2026). Global Budget Revenue Model and Care for Patients Receiving Chemotherapy. JAMA Network Open, 9(3), e260485. https://doi.org/10.1001/jamanetworkopen.2026.0485
Vancouver
Lin YL, Herring B, Melamed A, Petrillo LA, Keating NL, Offodile AC. Global Budget Revenue Model and Care for Patients Receiving Chemotherapy. JAMA Network Open. 2026;9(3):e260485. doi:10.1001/jamanetworkopen.2026.0485
BibTeX
@article{Lin2026,
author = {Lin, Yu-Li and Herring, Bradley and Melamed, Alexander and Petrillo, Laura A and Keating, Nancy L and Offodile, Anaeze C},
title = {Global Budget Revenue Model and Care for Patients Receiving Chemotherapy},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {3},
pages = {e260485},
doi = {10.1001/jamanetworkopen.2026.0485}
}
EUVIMED